Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2761–2784 of 7,489 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Standard Control Clear all

Conditions: Cardiovascular Diseases, Personal Health Records, Pharmaceutical Care, Mobile Apps
Interventions: Pharmacist-led cardiovascular risk service (CVRS), Mobile access to study Personal Health Record, Web access to study Personal Health Record; Other
Lead sponsor: University of Iowa; Other
Eligibility: 55 Years to 99 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Iowa City, Iowa • Sioux City, Iowa

Conditions: Diabetic Foot Ulcers
Interventions: NEOX®CORD 1K, standard of care; Other
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 19
States / cities: Carlsbad, California • Castro Valley, California • Fair Oaks, California + 16 more

Conditions: Glioblastoma, Gliosarcoma
Interventions: ERC1671, GM-CSF, Cyclophosphamide, Oral Control (Sucrose pill), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)), Bevacizumab/Bevacizumab Biosimilar; Drug
Lead sponsor: Epitopoietic Research Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 3
States / cities: Orange, California • Boston, Massachusetts

Conditions: Hepatitis C
Interventions: CTS-1027, pegylated interferon, Ribavirin, Placebo; Drug
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 45
States / cities: Birmingham, Alabama • Coronado, California • La Jolla, California + 33 more

Conditions: Ventilator Induced Diaphragm Dysfunction
Interventions: Lungpacer Diaphragm Pacing Therapy; Device
Lead sponsor: Lungpacer Medical Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 22
States / cities: Stanford, California • Aurora, Colorado • Gainesville, Florida + 17 more

Conditions: Anxiety, Presurgical Anxiety, Breast Cancer
Interventions: Massage therapy, Standard of care; Procedure
Lead sponsor: Vassar Brothers Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Poughkeepsie, New York

Conditions: Wound
Interventions: Standard of Care Treatment or Standard of Care Treatment plus Miro3D Wound Matrix; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Mesothelioma
Interventions: Biospecimen Collection, Cryosurgery; Procedure
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypertension, Obesity
Interventions: Radio Story, Control -listened to a brochure; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Epistaxis
Interventions: Microporous Polysaccharide Hemospheres, Nasal Tampon; Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Scar
Interventions: Micro biopsy, Lidocaine with epinephrine; Device · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 50 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Exudative Age-Related Macular Degeneration
Interventions: LHA510 ophthalmic suspension, LHA510 vehicle, Ranibizumab ophthalmic solution; Drug
Lead sponsor: Alcon, a Novartis Company; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Colorectal Neoplasms
Interventions: Standard Information, Preference-tailored Information; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 50 Years to 78 Years
Enrollment: 466 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Pittsburgh, Pennsylvania

Conditions: Postoperative Hematoma, Postoperative Seroma
Interventions: Intravenous TXA; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes Mellitus, Type 2, Health Knowledge, Attitudes, Practice, Literacy
Interventions: GogyUp Reader; Other
Lead sponsor: GogyUp Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 193 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetic Foot Ulcer
Interventions: Omeza® Complete Matrix, Standard of Care; Device · Other
Lead sponsor: Omeza, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Evergreen Park, Illinois • Denham Springs, Louisiana • Leesville, Louisiana + 7 more

Conditions: Periodontal Disease, Stroke, TIA
Interventions: Intensive dental treatment, Standard dental treatment, Arestin; Procedure · Drug
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Columbia, South Carolina

Conditions: Neuromuscular Scoliosis
Interventions: Thromboelastography laboratory testing; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 12 Years to 18 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Sickle Cell Disease
Interventions: The adapted Kids in Transition to School Intervention, Standard school resources; Behavioral
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 42 Months to 78 Months
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc, SCLC,Extensive Stage, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV
Interventions: BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin; Drug
Lead sponsor: SystImmune Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 7
States / cities: Springdale, Arkansas • Glendale, California • Long Beach, California + 4 more

Conditions: Lower Limb Amputation Below Knee
Interventions: Fixed stiffness prosthesis, Automatic stiffness prosthesis; Device
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years to 79 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Psychosocial Stress
Interventions: Therapy dog visitation; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 50 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sleep, Sleep Hygiene
Interventions: Timed evening technology and digital media use (tablet use), no technology and digital media use (screen media use); Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 48 Months to 59 Months
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Childhood Obesity, Parenting
Interventions: Parenting videos, Standard pediatric obesity treatment; Behavioral
Lead sponsor: Nemours Children's Health System; Other
Eligibility: 18 Years to 100 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Wilmington, Delaware

Search by objective public record fields.

Mobile Cardiovascular Risk Service Trial

Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders

A Protocol Comparing Temporary Transvenous Diaphragm Pacing to Standard of Care for Weaning From Mechanical Ventilation

Preoperative Massage in Breast Surgery Patients

Miro3D Randomized Controlled Trial (RCT)

Cryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma

Radio Stories About Children's Healthy Eating and Exercise

Microporous Polysaccharide Hemospheres Epistaxis

Reducing Side-effects of Autologous Skin Tissue Harvesting

LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration

Evaluating a Preference-based Intervention for Increasing Colorectal Cancer Screening

Investigating the Use of Intravenous Tranexamic Acid in Gender Affirming Mastectomy

Improving Diabetic Patient Health Through Assistive-Reading Technology

Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers

PeRiodontal Treatment to Eliminate Minority InEquality and Rural Disparities in Stroke

Thromboelastography Transfusion Protocol for Pediatric Neuromuscular Scoliosis Surgery

School Readiness Intervention for Preschool Children With Sickle Cell Disease

BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

Automatic Prosthetic Foot Stiffness Modulation to Improve Balance in the Real World

Biobehavioral Effects of Therapy Dog Visitation in Elderly Intensive Care Unit Patients: A Pilot and Feasibility Study

The Goodnight Screen Media Study

Parenting Intervention for Pediatric Obesity